Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
Price:
41.32
USD
Market Closed
Market Cap:
$14.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
|
SE |
|
G
|
Golden Pharos Bhd
KLSE:GPHAROS
|
MY |
|
Kenvue Inc
NYSE:KVUE
|
US |
|
Windfall Geotek Inc
XTSX:WIN
|
CA |
|
Hoteles City Express SAB de CV
BMV:HCITY
|
MX |
|
Totech Corp
TSE:9960
|
JP |
|
U
|
Unusual Machines Inc
AMEX:UMAC
|
US |
|
S
|
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
|
CN |
|
Eukedos SpA
MIL:EUK
|
IT |
|
Ev Dynamics Holdings Ltd
HKEX:476
|
HK |
|
P
|
PT Era Digital Media Tbk
IDX:AWAN
|
ID |
|
Broadstone Net Lease Inc
NYSE:BNL
|
US |
|
A
|
Airea PLC
LSE:AIEA
|
UK |
|
G
|
Gdh Supertime Group Co Ltd
SZSE:001338
|
CN |
|
Z
|
Zhejiang Leapmotor Technology Co Ltd
HKEX:9863
|
CN |
Multiples-Based Value
The Multiples-Based Value of one
BIOVF
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 41.32 USD,
Swedish Orphan Biovitrum AB (publ)
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BIOVF Multiples-Based Value
LOCKED
Multiples Across Competitors
BIOVF Competitors Multiples
Swedish Orphan Biovitrum AB (publ) Competitors
Swedish Orphan Biovitrum AB (publ) Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
|
Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
|
132.4B USD | 4.8 | 283.8 | 7.8 | 17.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.2B USD | 6.1 | 89.2 | 14.8 | 20.5 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.4B USD | 6.2 | -96.2 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.9B USD | 5.8 | 20 | 12.5 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.6B AUD | 3.2 | 34.9 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
